Physician profile
Gregory E Cox
NPI 1386607844
$1,279.54
in general payments reported to CMS, 2019-2025
15 companies · $328 in 2025
The $328 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $177 · 2021: $145 · 2022: $148 · 2023: $102 · 2024: $151 · 2025: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $581.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $178.25 | 2025 | Argos, Tryptyr, Rocklatan |
| Allergan, INC. | $174.60 | 2020-2021 | |
| Aerie Pharmaceuticals, INC. | $134.99 | 2019-2021 | |
| Pfizer INC. | $126.33 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $116.30 | 2021-2025 | Cequa |
| Abbvie INC. | $115.01 | 2023-2025 | Durysta |
| Bausch & Lomb Americas INC. | $95.54 | 2022-2024 | Infuse, Vyzulta |
| Eyepoint US, INC. | $78.00 | 2019 | |
| Biotissue Holdings INC. | $61.84 | 2021-2025 | |
| Ocular Therapeutix, INC. | $50.48 | 2022-2025 | Dextenza |
| Kala Pharmaceuticals, INC. | $45.07 | 2021-2022 | |
| Johnson & Johnson Vision Care, INC. | $31.21 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $28.85 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $25.78 | 2020-2021 | |
| Dompe US, INC. | $17.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.